Koers Isofol Medical AB (publ) Nasdaq Stockholm
Aandelen
SE0009581051
Farmaceutische producten
Omzet 2021 | 22,41 mln. 2,07 mln. 1,92 mln. | Omzet 2022 | 12,8 mln. 1,18 mln. 1,1 mln. | Marktkapitalisatie | 120 mln. 11,05 mln. 10,27 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -200 mln. -18,49 mln. -17,18 mln. | Nettowinst (verlies) 2022 | -160 mln. -14,79 mln. -13,74 mln. | EV/omzet 2021 | 49,7 x |
Nettoliquiditeiten 2021 | 378 mln. 34,93 mln. 32,45 mln. | Nettoliquiditeiten 2022 | 187 mln. 17,26 mln. 16,03 mln. | EV/omzet 2022 | -5,24 x |
K/w-verhouding 2021 |
-5,8
x | K/w-verhouding 2022 |
-0,75
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 62,57% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | 72 | 09/01 |
Magnus Hurst
DFI | Director of Finance/CFO | 68 | 10/01 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-02-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | 04/01 |
Alain Herrera
BRD | Director/Board Member | 74 | 01-01-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,48% | 71,19 mld. | |
+12,55% | 9,3 mld. | |
-13,75% | 5,01 mld. | |
+42,38% | 4,47 mld. | |
+4,51% | 3,96 mld. | |
+21,10% | 2,44 mld. | |
-19,05% | 2,41 mld. | |
-28,72% | 2,23 mld. | |
+11,13% | 2,02 mld. |